Pfizer Inc. (PFE)

NYSE: PFE · IEX Real-Time Price · USD
-0.14 (-0.34%)
Mar 21, 2023, 3:59 PM EDT - Market closed
Market Cap 229.50B
Revenue (ttm) 100.33B
Net Income (ttm) 31.37B
Shares Out 5.64B
EPS (ttm) 5.47
PE Ratio 7.43
Forward PE 10.96
Dividend $1.61 (3.96%)
Ex-Dividend Date Jan 26, 2023
Volume 16,650,551
Open 40.86
Previous Close 40.81
Day's Range 40.31 - 40.91
52-Week Range 39.23 - 56.32
Beta 0.59
Analysts Buy
Price Target 53.10 (+30.56%)
Earnings Date May 2, 2023

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zit... [Read more]

Sector Healthcare
Founded 1849
Employees 79,000
Stock Exchange NYSE
Ticker Symbol PFE
Full Company Profile

Financial Performance

In 2022, Pfizer's revenue was $100.33 billion, an increase of 23.43% compared to the previous year's $81.29 billion. Earnings were $31.37 billion, an increase of 42.74%.

Financial Statements

Analyst Forecast

According to 29 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $53.1, which is an increase of 30.56% from the latest price.

Price Target
(30.56% upside)
Analyst Consensus: Buy
Stock Forecasts


7 High-Yield Dividend Stocks to Compete Against Rising Yields

Although passive income has always been a strong component of a well-balanced portfolio, investors may want to pay particular attention to high-yield dividend stocks to buy. Should the Federal Reserve...

1 hour ago - InvestorPlace

Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May...

6 hours ago - Business Wire

Pfizer's (PFE) COVID-19 Drug Paxlovid Gets FDA Panel Vote

FDA's Antimicrobial Drugs Advisory Committee (AMDAC) votes 16 to 1 for Pfizer's Paxlovid for the treatment of mild-to-moderate COVID-19 in adult patients at high risk of hospitalization or death.

4 days ago - Zacks Investment Research

Biotech experts wary of Pfizer cutting Seagen workforce — but history reveals silver lining

Seattle-area biotech experts are eying the past with a wary eye in the wake of this week's news that Pfizer plans to acquire Bothell, Wash.

Other symbols: SGEN
4 days ago - GeekWire

Is Pfizer Stock Undervalued At $40?

Pfizer stock (NYSE: PFE) has seen a fall of 21% this year, compared with 2% returns for the broader S&P500 index.

4 days ago - Forbes

7 High-Yield Dividend Stocks That Can Double Your Money in 2023

Investors should brace up for another challenging year for equities. Turbulence in the banking system, inflation and a potential recession are the major headwinds.

4 days ago - InvestorPlace

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

Pfizer and Astellas announce positive topline results from Phase 3 EMBARK trial     NEW YORK and TOKYO , March 16, 2023 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, Pre...

4 days ago - PRNewsWire

FDA advisors recommend full approval of Pfizer Covid treatment Paxlovid for adults 50 and over and other high-risk people

Paxlovid is recommended for people over 50 or those with medical conditions like high blood pressure or diabetes that place them at a greater risk of Covid.

5 days ago - CNBC

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer's PAXLOVID™

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration's (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data s...

5 days ago - Business Wire

FDA committee says benefits outweigh risks for Pfizer's Paxlovid

A Food and Drug Administration advisory committee voted 16-1 that the benefits of Pfizer's PFE COVID antiviral Paxlovid outweigh the risks in adults who are at high risk of severe disease. The FDA is ...

5 days ago - Market Watch

FDA panel to meet Thursday to discuss full approval of Paxlovid

A Food and Drug Administration committee is set to meet Thursday to decide whether the regulator should grant full approval to Paxlovid, the antiviral pill developed by Pfizer PFE to treat high-risk C...

5 days ago - Market Watch

Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants

Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.

6 days ago - Zacks Investment Research

Pfizer's Latest Acquisition Strengthens the Case for PFE Stock

On March 13, 2023, Pfizer, Inc. (NYSE: PFE) announced it was merging with Seagen Inc. (NASDAQ: SGEN). Under terms of the definitive agreement, Pfizer will buy Seagen for $229 in cash per share.

6 days ago - MarketBeat

Pfizer will have to pay rebates to Medicare for five drugs under Biden plan to lower Rx costs

Five of Pfizer's drugs will cost less for Medicare recipients starting next month as part of President Joe Biden's plan to lower prescription drug cost.

6 days ago - CNBC

FDA updates authorization of BioNTech, Pfizer's bivalent booster for young children

The Food and Drug Administration on Tuesday said children between the ages of 6 months and 5 years old can now get a booster dose of BioNTech BNTX and Pfizer's PFE COVID-19 bivalent vaccine. The third...

Other symbols: BNTX
6 days ago - Market Watch

3 Vaccine Stocks to Watch for Their Post-Pandemic Moves

During the Covid-19 pandemic, vaccine stocks shot up on the promise that they could end the lockdowns. Many vaccines were developed, but few were approved.

Other symbols: MRNANVAX
6 days ago - InvestorPlace

7 Undervalued Dividend Stocks for Your Must-Buy List

With markets getting dragged down by another financial crisis, investors should seek safety.  In fact, one of the best places for that is in undervalued dividend stocks.

6 days ago - InvestorPlace

FDA authorizes Pfizer's Covid omicron booster as fourth shot for kids under 5

The FDA authorized Pfizer's omicron booster shot for kids younger than five who were previously vaccinated with three doses of the company's original shot.

6 days ago - CNBC

Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition

Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.

Other symbols: SGEN
6 days ago - Zacks Investment Research

FDA staff report says data shows Pfizer's Covid treatment Paxlovid is effective in high-risk adults

FDA staff said Pfizer's clinical trial results on its Covid antiviral pill Paxlovid support its use in adults at high risk of progressing to severe disease.

1 week ago - CNBC

Pfizer (PFE) to Buy Seagen for $43B, Boost Cancer Portfolio

Pfizer (PFE) is set to buy Seagen (SGEN) in a $43 billion deal. Seagen's key products focus on cancer treatment.

1 week ago - Zacks Investment Research

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Recently, users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

1 week ago - Zacks Investment Research

SHAREHOLDER ALERT: Weiss Law Investigates Seagen Inc.

NEW YORK , March 14, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Seagen Inc. ("Seagen" or the "Company"...

Other symbols: SGEN
1 week ago - PRNewsWire

How Pfizer's $43 billion acquisition of Seagen could impact the biotech industry in Seattle

Biopharma acquisitions often come with layoffs and lab shutdowns as smaller companies get absorbed.

Other symbols: SGEN
1 week ago - GeekWire

SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Seagen Inc. (Nas...

Other symbols: SGEN
1 week ago - Business Wire